Tizona completes spinout of cancer program as part of Gilead buyout; Dyne files for $100M IPO
Tizona has completed the spinout of a new company that will focus on developing its now-former lead program involving an anti-CD39 antibody.
The new company, Trishula Therapeutics, is designed to further progress and focus on the existing TTX-030 collaboration that Tizona had signed with AbbVie back in early 2019. Currently, the candidate is being studied in Phase I/Ib trials, both by itself and in combination with an anti-PD-1 agent and standard chemotherapy, in adults with advanced cancers.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.